Oxford, UK – 16 July 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has signed an agreement with Plowshare Therapies (“Plowshare”), a biotechnology company developing gene therapies for rare genetic diseases. Under the agreement, OXB will provide process development and AAV GMP manufacturing services to Plowshare, with the potential to support additional programmes and later-stage manufacturing as Plowshare’s pipeline advances.
Read more at globenewswire.comOXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
Barchart·07/16/2026 06:00:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.